Proactive Investors - Run By Investors For Investors

Bioasis Technologies to meet with FDA June 2019 on it xB3 platform technology

Bioasis Technologies Inc. (OTCQB:BIOAF) (TSX.V:BTI) Director, President & CEO Dr. Mark Day sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The Connecticut based biopharmaceutical company is developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

View full BIOAF profile View Profile

Bioasis Technologies Inc. Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use